Supha PharmachemBOM:539561 -3.23%58 Net Margin % is 7.76% as of Sep. 2025, which is 1058% above its 10-year median of 0.67. GuruFocus rates BOM:539561 with a GF Score™ of 58/100 and a GF Value™ of ₹1.53 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 955 Drug Manufacturers companies, Supha Pharmachem ranks worse than 60.21% on this metric.
The historical rank and industry rank for Supha Pharmachem's Net Margin % or its related term are showing as below:
BOM:539561'
s Net Margin % Range Over the Past 10 Years
Min: 0.21 Med: 0.67 Max: 9.58
Current: 2.28
BOM:539561's Net Margin % is ranked worse than 60.21% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BOM:539561: 2.28
Supha Pharmachem (BOM:539561) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Supha Pharmachem Net Margin % Related Terms
Supha Pharmachem Net Margin % Historical Data
* Premium members only.
The historical data trend for Supha Pharmachem's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supha Pharmachem Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's Net Margin % distribution charts can be found below:
* The bar in red indicates where Supha Pharmachem's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supha Pharmachem (BOM:539561) has a Net Margin % of 7.76% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Supha Pharmachem and its competitors. This is 1058% above median its historical median of 0.67. Over the past decade, Supha Pharmachem's Net Margin % has ranged from 0.21 to 9.58. According to the industry distribution chart, Supha Pharmachem ranks #575 out of 955 companies in the Drug Manufacturers industry, placing it in the top 60.2%.
Is Supha Pharmachem's Net Margin % too high?
Supha Pharmachem's current Net Margin % of 7.76% is 1058% above median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 9.58. The Drug Manufacturers industry median Net Margin % is 5.69. Supha Pharmachem's value of 7.76% is 36.4% above this industry median. Based on the distribution chart, Supha Pharmachem ranks #575 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Supha Pharmachem has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Supha Pharmachem ranks #575 out of 955 companies for Net Margin %. This places Supha Pharmachem in the lower half of its industry. The industry median Net Margin % is 5.69. Supha Pharmachem's value of 7.76% is 36.4% above this benchmark. Historically, Supha Pharmachem's own Net Margin % has ranged from 0.21 to 9.58 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 5.69, Supha Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supha Pharmachem's current Net Margin % of 7.76% is 36.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Supha Pharmachem and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supha Pharmachem's current Net Margin % is 7.76%, which is 1058% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.53, compared to a current price of ₹0.30 — trading 80.4% below its estimated fair value. The current Net Margin % is 7.76%, which is 1058% above median its 10-year median of 0.67 and 36.4% above the Drug Manufacturers industry median of 5.69. Supha Pharmachem's overall GF Score™ is 58/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current Net Margin % is 7.76% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supha Pharmachem (BOM:539561) Overvalued in 2026?
Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued.
The current stock price of ₹0.30 is trading 80.4% below its estimated GF Value™ of ₹1.53.
GuruFocus considers Supha Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:539561:
Net Margin %: 7.76% (1058% above median its 10-year median of 0.67)
GF Value™: ₹1.53 vs. price of ₹0.30 (80.4% below fair value)
Industry Position: 36.4% above the Drug Manufacturers median (#575 of 955)
No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
58GF Score
Get the complete analysis for BOM:539561
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539561 has been successfully added to your 
